Drugs / PM359
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06559176 | Oct 2024 → Jan 2030 expected | chronic granulomatous disease | Prime Medicine, Inc. | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06559176 ↗ |
| Action | Restore | “modified using Prime Editing to 'correct' the delGT mutation causing p47phox CGD” NCT06559176 ↗ |
| Route | Intravenous | “administered autologously by intravenous (I.V.) infusion” NCT06559176 ↗ |
| Target | NCF1 | “PM359 is an autologous CD34+ hematopoietic stem cell (HSC) suspension that is Prime Edited at the NCF1 locus” NCT06559176 ↗ |